CMS classification enhances CRC prognosis and treatment personalization but faces challenges due to ITH and technical limitations. Advances in IHC, imCMS, and targeted gene panels may facilitate broader clinical adoption, improving patient outcomes through tailored therapies.
No takes yet. Share an insight, caveat, or question.
Kantha et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: